Contents

About Sanofi ................................. P. 1
- Sanofi Overview ............................ P. 1
- About Sanofi China ...................... P. 1

A Message from the China Country Lead ............................. P. 2

Corporate Social Responsibility Management .................... P. 3

Ethics and Transparency ........................................... P. 4
- Ethics and business integrity ..................... P. 4
- Guarantee patient safety ......................... P. 6

Access to Healthcare ............................................. P. 7
- Building an innovation-driven future .......... P. 7
- Improving access to healthcare ............... P. 10
- Leading vaccine innovation ................. P. 13
- Increasing investment in R&D and production in China P. 14

Engage with Communities ........................................ P. 15
- Helping employees to actualize their dreams and grow their potential P. 15
- Devotion to community for a better future .... P. 17

Healthy Planet .................................................. P. 20

GRI Content Index ............................................. P. 22

Awards & Recognition .......................................... P. 23

Additional Information about Sanofi CSR Report .......... P. 23
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focusing on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

"Sanofi
Empowering Life"

About Sanofi China

Sanofi found its home in China at the very beginning of the country’s reform and opening up, as one of the first multinational pharmaceutical companies. Since then, we went through a journey of 38 years, hand in hand with China, through achievements and challenges. We are proud to improve the health of the Chinese people and grow with China.

In the last several decades, with strong and long-term commitment, we are constantly investing R&D capabilities and manufacturing facilities in China and set up 1 Digital Innovation Hub to accelerate innovation.

- Rooted in 2,000+ cities and counties
- Introduced 40+ high-quality medicines and vaccines
- Provide immunization and prevention for over 10 million Chinese people every year
- Benefit nearly 10 million chronic disease patients
- and hundreds of rare disease patients

2019

Sanofi China Employees

8,000+
covering 12 cities in China

We have

3 Manufacturing sites
4 R&D sites
1 Digital Innovation Hub

Sanofi China sales

€2.704 billion
A Message from the China Country Lead

Since I took the leadership for Sanofi China in early 2019, I have been very impressed by the fast development of China’s healthcare and digital environment. Over our Sanofi journey of the last 38 years here in China, we have shown to be more than a reliable partner supporting people facing healthcare challenges, also being an advocate and practitioner of responsibility for the whole society.

Entering 2020, as we had to face the unprecedented challenge of COVID-19, we all feel obliged to work together, hand in hand with our customers, patients, our employees, business partners, and society in general, for a sustainable future. In this context, it is particularly meaningful to further put the emphasis on corporate social responsibility (CSR). It underlines our positive response to the needs of society in the up-coming years. Below, I would like to share with you some of my thoughts linked to it.

Since we opened the first office in China, we are dedicated to making a difference on health journey of Chinese people. Shortly after I assumed my role in China in 2019, I visited a county in Henan province to understand its true needs. China is the 2nd largest healthcare market with diverse needs, though, there are significant unmet needs and challenges to overcome. We have taken initiatives to broaden the access to healthcare for the underserved, like supporting chest pain centers set up to serve millions of people who lack of medical resources in counties. We are also proud to help the few who suffer from rare diseases and who are out of spotlight.

To create a sustainable ecosystem, we are scaling up our engagement with employees, customers and other stakeholders across industries. Over the years, the Sanofi Hope Volunteer Group has brought care to over 50,000 children across the country. We are also committed to building a magnet for talent for employees to unleash their full potential and achieve goals. We are proud to be recognized as a Top Employer 2020 in China now for three consecutive years.

We envision a future of healthy planet and anticipate a possible response to the environmental challenges through our operation and production. We launched the Planet Mobilization initiative, aiming to reduce Sanofi’s environmental footprint and to establish the company’s commitment to sustainability growth. We are doing our part to preserve our planet for future generations. In 2017-2019, Sanofi’s three factories in China have made remarkable achievements in environmental protection and energy conservation, for example, in terms of carbon emissions per 10 thousand yuan of output value and electricity consumption per 10 thousand yuan of output value and other energy conservation and emission reduction, it continued to reduce or remain stable, and fulfilled our commitment to environmental protection in China’s operating areas.

We believe we can do well by doing in right way. This is what the society expects from us. We strive for excellence in quality management as medicine quality is critical for customers. With Sanofi’s longstanding strong commitment to China, we adapt our CSR focus to business and societal goals, relying on the ethics & transparency, which serves as the foundation of CSR strategy.

The recent COVID-19 outbreak has a tremendous impact worldwide. At the beginning of the outbreak, Sanofi took prompt action and made donations to support China. While ensuring production continuity, we spare no effort to put employee’s safety and patients’ need at first. Given the new reality with the pandemic, we have started to profoundly change past habits, helping employees to work in a different set-up, more remotely if desired, more empowered, with that we will further improve our carbon footprint significantly in the near future. Last but not least, we are also working relentlessly to ensure that the way the entire company work is built on strong ethical values addressing the increasing expectations of the society. The large-scale compliance ambassador program we have implemented involving close to 500 employees as ambassador is a living proof of it.

Sanofi China will continue to work closely with all stakeholders for the benefits of all Chinese people. Moreover, I will move forward with my team to accelerate the R&D and introduction of new medicines and vaccines, actively explore digital innovative solutions, and lead the digital transformation in China’s healthcare sector.
### Corporate Social Responsibility Management

#### Stakeholder Engagement

<table>
<thead>
<tr>
<th>Stakeholders</th>
<th>Way of Engagement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Government / Regulatory Agencies</strong></td>
<td>- regular visit</td>
</tr>
<tr>
<td></td>
<td>- information disclosure</td>
</tr>
<tr>
<td></td>
<td>- regulatory requirements</td>
</tr>
<tr>
<td><strong>Patients / Consumers</strong></td>
<td>- disease publicity</td>
</tr>
<tr>
<td></td>
<td>- campaigns/projects</td>
</tr>
<tr>
<td></td>
<td>- building platforms (on-line &amp; off-line)</td>
</tr>
<tr>
<td><strong>Investors</strong></td>
<td>- business results reporting</td>
</tr>
<tr>
<td></td>
<td>- business plan</td>
</tr>
<tr>
<td><strong>Employees</strong></td>
<td>- training</td>
</tr>
<tr>
<td></td>
<td>- career development planning</td>
</tr>
<tr>
<td></td>
<td>- employee survey</td>
</tr>
<tr>
<td></td>
<td>- internal communication channels</td>
</tr>
<tr>
<td><strong>HCP / Industry</strong></td>
<td>- training support</td>
</tr>
<tr>
<td></td>
<td>- project cooperation</td>
</tr>
<tr>
<td></td>
<td>- visit and communication (on-line &amp; off-line)</td>
</tr>
<tr>
<td></td>
<td>- industry association activities</td>
</tr>
<tr>
<td><strong>Partners</strong></td>
<td>- vendor meeting</td>
</tr>
<tr>
<td></td>
<td>- vendor evaluation and audit sharing platform</td>
</tr>
<tr>
<td></td>
<td>- strategic cooperation</td>
</tr>
<tr>
<td><strong>Communities</strong></td>
<td>- disease knowledge publicity</td>
</tr>
<tr>
<td></td>
<td>- volunteer activities</td>
</tr>
<tr>
<td></td>
<td>- community projects</td>
</tr>
<tr>
<td></td>
<td>- official website, wechat public account</td>
</tr>
<tr>
<td><strong>Social organizations / media</strong></td>
<td>- project cooperation</td>
</tr>
<tr>
<td></td>
<td>- press release</td>
</tr>
</tbody>
</table>

#### Sanofi CSR Strategy

- **Access to Healthcare for the Underserved**
  - Foster access to healthcare for underserved patients
  - Sustain ecosystems around Sanofi’s sites
  - Develop and engage employees

- **Ethics and Transparency**
  - Manage our activities with ethics and business integrity
  - Protect patient safety
  - Ensure medical ethics and bioethics

- **Engage with Communities**
  - Reducing CO2 emissions
  - Streamline water use and drug residues
  - Reduce waste
  - Increase awareness of climate change and its consequences on health

- **Healthy Planet**
  - Reduce CO2 emissions
  - Streamline water use and drug residues
  - Reduce waste
  - Increase awareness of climate change and its consequences on health

#### Sanofi China’s Material Issues

- **Access to Healthcare**
  - Product innovation
  - Disease management capabilities
  - Primary care
  - Healthcare model innovation

- **Business and R&D Ethics**
  - Business ethics

- **Impact of Local economy**
  - Sustainable supply chain Dialogue between stakeholders

- **Patient Safety**
  - Product quality
  - Combating Counterfeit Medicine
  - Pharmaceutical vigilance

- **Talent Development**
  - Talent development
  - Awareness of the impact of climate change on health

- **Environmental Footprint**
  - Carbon emission
  - Waste management
  - Water management including PTE

#### Sano/f_i CSR Strategy

- **Sano/f_i China’s Material Issues**
  - **Access to Healthcare for the Underserved**
    - Foster access to healthcare for underserved patients
  - **Ethics and Transparency**
    - Manage our activities with ethics and business integrity
    - Protect patient safety
    - Ensure medical ethics and bioethics
  - **Engage with Communities**
    - Reducing CO2 emissions
    - Streamline water use and drug residues
    - Reduce waste
    - Increase awareness of climate change and its consequences on health
  - **Healthy Planet**
    - Reduce CO2 emissions
    - Streamline water use and drug residues
    - Reduce waste
    - Increase awareness of climate change and its consequences on health
Sanofi China has established a China has established an Ethics & Business Integrity department to ensure that the company strictly abides by local laws and regulations, and adheres to the strictest ethics and quality standards. The company has established corresponding policies, systems, and procedures for compliance matters such as anti-corruption and anti-bribery, as well as interaction with external stakeholders, and is committed to building and reinforcing a vibrant and robust corporate compliance culture.

### 7 Elements of Sanofi’s China Compliance System

1. **Formulate compliance policies and processes**
2. **Perform internal compliance supervision and audit**
3. **Take timely measures to address and deal with the problem**
4. **Establish compliance officers and a compliance committee**
5. **Publish punishment mechanism to implement standards**
6. **Organize effective compliance training and education**
7. **Conduct effective compliance communications**

### Compliance Management

Sanofi China has established an Ethics & Business Integrity department to ensure that the company strictly abides by local laws and regulations, and adheres to the strictest ethics and quality standards. The company has established corresponding policies, systems, and procedures for compliance matters such as anti-corruption and anti-bribery, as well as interaction with external stakeholders, and is committed to building and reinforcing a vibrant and robust corporate compliance culture.

### Ethics and Transparency

Sanofi incorporates the highest ethical standards and codes of conduct into the work we do every day, and is committed to building a trusting relationship between the company, patients, and society, via robust compliance management.

### Introducing Compliance Ambassadors to Promote the New Forces of Compliance Culture

In 2016, Sanofi China officially launched the Compliance Ambassador Project, which helps employees learn the latest compliance policies and best practices by conducting compliance training, sharing compliance experience, and organizing annual compliance culture camps.

Compliance Ambassador’s main responsibilities include:

1. Serving as the communication bridge to enhance employees’ willingness to provide feedback
2. Sharing the latest compliance information
3. Assisting in compliance supervision to identify potential compliance issues
4. Leading by example and spreading the company’s compliance culture

In 2017, the project was officially upgraded to the Sanofi China Compliance Ambassador Dandelion Project, with Compliance Ambassadors circulating throughout all business units and global functional departments.

In 2018, Sanofi China set up the role of compliance pioneer under the Compliance Ambassador project, which is mainly composed of front-line Medical Information Communication Representatives (MICRs) who are managed and cultivated by compliance ambassadors, and together their mission is to promote compliance culture and increase compliance awareness in the workplace.

### In 2019 Sanofi China

<table>
<thead>
<tr>
<th>Number of Compliance Ambassadors</th>
<th>Completion rate of compulsory compliance courses</th>
</tr>
</thead>
<tbody>
<tr>
<td>115</td>
<td>222</td>
</tr>
<tr>
<td>134</td>
<td>444</td>
</tr>
<tr>
<td>142</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of Compliance Pioneers</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2017: 115</td>
<td>2018: 222</td>
</tr>
<tr>
<td>2018: 134</td>
<td>2019: 444</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Average Teaching Time of Compliance Ambassadors (hours)</th>
<th>Number of Compliance Ambassador Trained (person-time)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017: 1</td>
<td>2017: 2,100+</td>
</tr>
<tr>
<td>2018: 2</td>
<td>2018: 2,700+</td>
</tr>
<tr>
<td>2019: 3.5</td>
<td>2019: 3,700+</td>
</tr>
</tbody>
</table>
Supplier Management

Sanofi requires that all suppliers must comply with the highest possible ethical standards, strictly abide by Chinese and international anti-corruption laws and regulations, and follow the basic principles of international labor organizations. We also require them to implement an effective HSE structure and management system, work in an optimal environment that meets health and safety conditions, and minimize any possible negative impact on the environment. We conduct supplier training and workshops to ensure that the procurement process meets Sanofi standards.

Facts & Figures

Number of suppliers conducting quality audits

<table>
<thead>
<tr>
<th>Year</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>33</td>
<td>42</td>
<td></td>
</tr>
</tbody>
</table>

Local Procurement Proportion by Sanofi China

<table>
<thead>
<tr>
<th>Year</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>98.9%</td>
<td>96.0%</td>
<td>95.9%</td>
<td></td>
</tr>
</tbody>
</table>

Responsible Medical Information Promotion

Sanofi China insists on promoting medical information information in an ethical, objective, and scientific manner, with the aim of providing thoroughly unbiased and consistently reliable academic and product information to patients, healthcare professionals, and regulatory authorities.

Facts & Figures

Number of MICRs taking training sessions

<table>
<thead>
<tr>
<th>Year</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>66,554</td>
<td>67,940</td>
<td>76,498</td>
<td></td>
</tr>
<tr>
<td>7,635</td>
<td>7,314</td>
<td>6,170</td>
<td></td>
</tr>
</tbody>
</table>

Average time of the training sessions provided to MSL (hours)

<table>
<thead>
<tr>
<th>Year</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.97</td>
<td>11.27</td>
<td>13.48</td>
<td>17.92</td>
</tr>
</tbody>
</table>
Passive management: to ensure that quality-related issues are discovered and handled in a timely manner.

Active management: to identify internal and external potential risks to ensure that the safety of patients is not compromised.

Sano/ifi adopts advanced technology to ensure the traceability, quality and safety of raw materials.

Sano/ifi has set up a quality college to provide continuous quality education for employees.

As regards quality, we actively share and exchange excellent practices with the entire industry.

Sano/ifi Global Quality Department conducts undifferentiated quality control on all national-level business units.

Through internal self-examination, the company has continuously come up with preventive or corrective solutions to any encountered problems.

Key areas of quality management:

- Quality Culture
- Risk Management
- Supply Chain Management
- Quality audit

Facts & Figures:

In 2018, Sano/ifi Hangzhou site obtained the EU GMP certification and was awarded recognition as a “Reliable Enterprise for Consumption” by the Satisfactory Consumption Yangtze River Delta Action in 2019.

From 2017 to 2019, Sano/ifi Shenzhen site won the "National Excellent Foreign Investment Enterprise Quality Improvement" award for three consecutive years.

From 2017 to 2019, Sano/ifi China did not have any recalls due to safety issues in the products sold or shipped.

The Sano/ifi China Product Safety Team cooperates with law enforcement agencies across China to combat the manufacture and sale of counterfeit products. From 2012 to 2019, the counterfeiting cases brought by Sano/ifi, which were handled together with China IPR enforcement agencies, have been consistently rated as China’s Best 10 Intellectual Property Right Cases by the Quality Brand Protection Committee of China Foreign Investment Enterprise Association.

In order to protect the safety of patients, Sano/ifi pays close attention to the integrity of the entire life cycle of drugs from clinical trials, prescriptions, all the way through to patient use. Through an efficient global collaboration network, the global pharmacovigilance department continuously collects product safety information, providing healthcare professionals and patients with the latest and most comprehensive safety information in a timely manner, to ensure patient safety.

Sano/ifi also closely tracks draft laws and regulations issued by government agencies, updates headquarters and local quality documents in a timely manner, and submits individual safety reports, periodic reports, and other documents in strict accordance with the requirements of relevant Chinese laws and regulations.

Sanofi has planned a comprehensive and systematic Adverse Event (AE) report training system, in order to ensure that all safety-related information can be reported in a timely and accurate manner.

Any Sanofi China employee or member of personnel representing the company shall submit individual safety reports on registered/listed products in China to the Sanofi China Pharmacovigilance Team, within 24 hours upon having received such reports or having learned the likelihood of obtaining identifiable individual safety information.

Commitment to Quality

Sanofi’s manufacturing sites in China strictly adhere to unified global standards, implementing quality management to cover the entire product life cycle: from R&D to production, supply chain, pharmacovigilance, and medical support. This quality management system covers not only the company, but also suppliers and third-party partners. At the same time, Sanofi promotes the continuous improvement of total quality management, including ongoing upgrades of production equipment and the execution of intelligent digital applications.

Guarantee patient safety

Placing the health of patients at heart, Sanofi pays great attention to the needs of patients, and does everything required to ensure the safety and integrity of patients’ medication.

Number of quality training sessions in manufacturing sites

<table>
<thead>
<tr>
<th>Year</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>105</td>
<td>112</td>
<td>123</td>
</tr>
</tbody>
</table>

Number of people taking quality training sessions

<table>
<thead>
<tr>
<th>Year</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>29,495</td>
<td>28,504</td>
<td>32,763</td>
</tr>
</tbody>
</table>

Ethics and Transparency
Over the past 38 years in China, Sanofi has introduced more than 40 high-quality innovative medicines and vaccines to the Chinese people, consistently bolstering a diversified portfolio to meet the health needs of the Chinese people.

Sanofi’s existing products and pipelines cover five major therapeutic areas including cardiovascular disease, diabetes, oncology, respiratory diseases and preventive immunization, positioning the company ideally to support the key initiative of “Promoting the Prevention and Control of Five Major Diseases” under the Healthy China 2030 Blueprint. We will accelerate innovation. By 2025, we plan to introduce more than 25 innovative drugs and vaccines to the Chinese market.

Our portfolio in the future

- Cardiovascular Diseases
- Rare Diseases
- Orthopedics
- Oncology
- Human Vaccines
- Nephrology
- Diabetes
- Central Nervous System
- Inflammation & Immunology
- Neuroscience & Multiple Sclerosis

Sanofi takes the health needs of the Chinese people as its strategic core and actively provides high-quality innovative products and services to help achieve the goal of “Healthy China 2030”.

Driven by innovation, Sanofi China has been accelerating the introduction of innovative products to meet diverse health needs. Guided by global digitalization strategy, the company has been advocating the spirit of innovation internally. Furthermore, it has established strong partnerships with large external digital ecosystems to accelerate the development of emerging business models to lead digital innovation, and become the best digital healthcare enterprise in China.

From disease prevention to chronic disease management, Sanofi actively improves the access to healthcare through innovative healthcare management models.
Digital innovation is the strategic core of Sanofi’s future development. By promoting and leading in digital transformation, we are committed to improving patient outcomes.

**Stimulating creativity and building an innovation ecosystem for healthcare**

In 2018, Sanofi launched its Digital Innovation Hub, to build a bridge for local innovative enterprises and relevant stakeholders in which, through collaboration, they can accelerate the implementation of strategic initiatives and cultivate new business models under strict operations. Through this open innovation platform, Sanofi has been actively cooperating with startups to explore and develop innovative healthcare solutions to address business challenges, help healthcare professionals make better decisions, and improve the overall quality of life for many Chinese patients.

In 2019, Sanofi entered into partnerships with stakeholders of various industries to actively explore the digital future of the healthcare industry:

- Collaborated with Ping An Smart City to develop and provide innovative solutions for patients and HCPs in diabetes management and other areas of interest.
- Signed a memorandum of understanding with Tencent to jointly provide innovative digital solutions for unmet medical needs and improve disease awareness, education and management.
- Built a strategic partnership with Atman, a pioneering company in the field of medical language intelligence, where the two parties will work together to create a bilingual (English & Chinese) medical information platform. With the help of artificial intelligence and natural language processing, the platform will serve as Sanofi’s primary digitized medical communication engine.

**Digital Innovation**

In May 2019, Sanofi China launched the first “Dare to Dream-College Student Contest on Digital Healthcare Innovation”. Its goal was to explore, discover, and support digital innovation solutions centered on patients with chronic diseases, while helping contestants create ideal chronic disease management models that address as yet unmet medical needs in areas such as disease education, patient drug use management, and diagnosis and treatment services.

In February 2020, the second “Dare to Dream-College Student Contest on Digital Healthcare Innovation” was launched online, where 78 innovation proposals were received, inspiring the participation of a total of 267 students from 35 universities in 5 countries.
• Healthcare Management Model Innovation

| Focus on Segmentation Needs and Lead Medical Innovation |

Sanofi CNS and Internal Medicine Business Units and Sanofi Innovation Center have worked with external digital innovation companies to jointly create a chronic disease solution based on the intelligent anti-shake spoon and patient management platforms. The intelligent spoon not only can help patients eat without stress, but can also record tremor data outside of a hospital setting. The patient management service team records patients’ medication use experience, tracking adverse reactions, in order to enable the collection of patients’ in and out of hospital data during the entire course of disease. Such an approach will not only provide patients with practical and scientific assistance, but also furnish doctors with an auxiliary basis for diagnosis, as well as providing a solid foundation for real world studies.

As of the end of 2019, we have tested this solution in 5 key hospitals, and more than 100 patients have been recommended for enrollment with an enrollment rate of 52%.

More than 780 patient diaries and drug test reports have been obtained.

We will bring this solution to another 30 key hospitals in 2020, with 700-1,000 Parkinson’s disease patients expected to be covered.

The TRIO Program

The TRIO Program (an optimized glucose management program for diabetic patients) establishes a standardized process for the out-of-hospital management of diabetic patients. Through a smart three-party (physician, nurse, patient) interaction system, it enables a systemic implementation of the homogenous management/care concept under the background of multi-tiered diagnosis and treatment. Using an AI and IoT enabled app, patients are guided through a personalized treatment and different intervention frequencies, methods and contents. The Smart TRIO Program is the most recently updated version, featuring 3 months of short-term intensive intervention, combined with long-term management. Covering the entire course of the disease, it integrates early screening and disease prediction models, as well as clinical decision support systems for Standard of Care (SoC). Over the past 5 years, it has been used by more than 460 hospitals, reaching 630,000 diabetic patients.

Smart Community Chronic Disease Management

The Community Capacity Improvement Practice Base Project, supported by Sanofi China, aims to create a new community capacity-improvement practice base, starting with the lives of people through online smart community digital solutions, combined with intelligent disease management, to comprehensively improve the cognition of and adherence to standardized diagnosis and treatment by patients with chronic diseases.

The project will also focus on patient education and management, realizing the digital solution of “patient education + patient management” for chronic diseases. The smart community will introduce innovative digital technologies and methods for patient disease management such as robotic doctor assistants and artificial intelligence. The application scenarios include the collection of electronic files of newly diagnosed patients, patient education in and outside the hospital, knowledge quiz on WeChat, out-of-hospital diseases management and follow-up, electronic file update, AI medication taking reminder, electronic file extraction of patient revisits, etc. Through the demonstration of full disease course coverage, the overall vision and Internet-Healthcare oriented imagination of community hospital managers was fully realized.

Access to Healthcare | P. 9
Sanofi attaches great importance to the evolving needs of the Chinese people for health facilities and medical security. By combining its business advantages with local capabilities, the company is committed to providing advanced scientific solutions for unmet needs in disease prevention and control, and thereby contributing to the Healthy China initiative.

**Improving Access to Healthcare**

Sanofi China has been actively responding to the Chinese government’s strategic goal of building a strong primary care system, working diligently to bring high-quality medical resources such as high-quality innovative drugs and disease management models to grassroots healthcare institutions in order to improve their overall level of management and services, thus enabling patients to receive standardized treatment without leaving their county of residence.

**Epilepsy West China Program**

The Epilepsy West China Program was started in 2013 with the sponsorship of the Youth Committee of China Anti-Epilepsy Association. The program aims to improve the diagnosis and treatment level of epilepsy among community doctors and to spread epilepsy knowledge, so that society can gain awareness of the disease. This will ultimately bring more hope to epilepsy patients. Sanofi has been actively involved in this campaign for seven years, since 2014, and has completed 65 trips to the west, covering 25 provinces, 54 cities, and 45 counties, with nearly 100,000 doctors trained, and about 20,000 patients provided with free consultations. Sanofi is willing to work with industry associations and all HCPs to improve the professional diagnosis and treatment of epilepsy, cultivate the hope of epilepsy discipline, and help more epilepsy patients get proper treatment so they can return to their daily lives.

**Structured Treatment and Education Program for Community Diabetes Management**

Drawing on excellent chronic disease management practices abroad, and combining with the real needs of patients with primary diabetes in China, Sanofi China and Peking University have jointly launched the Structured Treatment and Education Program (STEP) for community diabetes management, in order to maximize the potential for self-management and self-care, and to provide standardized education and comprehensive management services for diabetic patients, with a view of achieving the effects of long-term, high-quality, and efficient chronic disease management.

**Chest Pain Center Development in County-level Hospitals-Interventional Diagnosis and Treatment Capacity Building Program (the CPC Project)**

Sanofi has long been committed to promoting wide access to primary care. In 2011, it set up a dedicated team to cover the primary care market, leading it to become one of the first multinational pharmaceutical companies focused on primary care development. Since then, Sanofi has carried out several construction projects for chest pain and stroke centers, helping to systematically improve basic conditions for the treatment of acute chest pain at county and city level hospitals, built a talent system, improved the capabilities of county hospitals in interventional diagnosis and treatment, assisted primary care clinics to optimize the treatment process of chest pain, and also provided a reference for the construction of diagnosis and treatment systems in other disease areas.

**As of 2019**

| 1,900+ county-level hospitals have joined in building chest pain centers |
| 1,376 counties |

It is expected that these projects will benefit

| 760 million patients |
| 500,000 doctors will be trained |

In August 2019, Sanofi China received the Outstanding Enterprise Award for a Three-Year CPC Project Promotion, jointly issued by the China Cardiovascular Health Alliance, the Institute of Cardiovascular Health (Suzhou Industrial Park) Research Institute, and the China Chest Pain Center Headquarters.
Heart Starter Project: providing comprehensive care for patients with acute coronary syndrome (ACS)

In February 2018, Sanofi China led the launch of the “Heart Starter” project for ACS patients, covering the pre-hospital, acute, in-hospital and out-of-hospital stages of patient management. Through an integrated on-line and off-line patient management model, we aim to provide free acute-phase aid packages for more than 600,000 patients, covering approximately 1,300 hospitals in 31 provinces and cities, to effectively reduce the burden of chronic diseases on patient families, hospitals, and society, and to promote the overall improvement of public health.

Disseminating professional knowledge to empower HCPs

2016

The Handbook for the Prevention and Treatment of Non-Communicable Diseases was published, with the aim of improving the professional level of primary care physicians in order to benefit more patients.

2019

In October 2019, the sixth edition of Handbook for Prevention and Treatment of Non-Communicable Diseases-Pharmacology was published, with the purpose of providing clinicians and pharmacists working at the community clinics with detailed guidance on drug prescription.

To further promote the implementation of continued education at community hospitals, Sanofi also organized various forms of education and training, with county-level hospitals and community hospitals at its center, to drive the overall improvement of primary care quality in China.

Actively participating in Volume-based procurement (VBP) and supporting the medical insurance policies

Sanofi China is committed to improving patients’ access to high-quality medicines and actively promoting the sound development of China’s healthcare industry. The nationwide rollout of the ‘4+7’ VBP program is a key priority for the Chinese government. Sanofi attaches great importance to this and actively participated in, serving Chinese patients by providing affordable, diversified and high-quality products.

In 2019
Sanofi’s 2 products were successfully selected into the expansion lists of 25 provinces

As of 2019
a total of 29 Sanofi products have been included in the National Drug Reimbursement List (NDRL)

As of 2019

nearly 40,000 training sessions have been conducted nationwide

covering about 600,000 primary care physicians
With an excellent R&D system and revolutionary innovative treatment solutions, Sanofi is at the world’s leading level in a variety of rare diseases, including rare blood diseases, nervous system diseases and genetic and metabolic diseases.

Sanofi China actively cooperates with the government, the society and all partners to rationally improve the diagnosis and treatment of rare diseases in China and explore diversified rescue models.

Bipolar disorder, also known as manic-depression, is a type of mental illness that most often occurs initially between the ages of 15 and 19. For some time, society has stigmatized mental illness. The public’s ignorance of the disease and the strong stigma of patients and their family members often hinders timely diagnosis and treatment, exerting a negative impact on the patient’s life.

In 2015, Sanofi, together with International Bipolar Disorder Association China Branch, introduced World Bipolar Disorder Day on March 30 of every year in China.

On March 30, 2020, under the guidance of the World Bipolar Association, the Psychiatric Society of the Chinese Medical Association, the Bipolar Disorder Cooperation Group of the Psychiatric Society of the Chinese Medical Association, and the Bipolar Disorder Working Group of the Psychiatrist Society of the Chinese Medical Association, Sanofi and the patient organization Bipolar Disorder World released the short charity film Two-Sided Life, Walking Towards the Sunlight, in which the voices of nearly 30 bipolar patients and their families were heard for the first time. The film unveiled the pain caused by the disease, and their deep desire for society to understand and ultimately accept bipolar disorder. The film was broadcast in a total of 32 provinces and cities across the country, garnering more than 1 million viewers.
Sanofi has made continuous innovation in the vaccine service model, and by collaborating with multiple parties, the company is pushing forward digital and intelligent vaccination clinics, to create a new smart ecosystem before, during, and after vaccination.

Sanofi Pasteur actively responded to the resolution of China and the WHO to implement a new polio vaccine immunization strategy. As of 2019, Sanofi Pasteur has supplied more than 50 million doses of Salk IPV to the Chinese market. Since 2016, it has completed the NIP vaccine supply task with high quality and abundant quantity for 4 consecutive years and in a timely manner, with a cumulative supply of more than 28 million doses. In addition, Sanofi played a positive role in promoting the transformation of the new polio vaccine immunization strategy in 2019, and has been widely recognized by national and provincial healthcare authorities.

Sanofi China launched the concept of "pregnancy immunization education" for the first time, combining the experience of maternal and child healthcare and immunization prevention, and using new "Internet +" technology to improve the vaccination rate for infants and young children by strengthening disease prevention and immunization education for pregnant women. Sanofi also provides high-quality maternal and child health education for Chinese parents and their children.

In November 2019, Sanofi and the Shenzhen Municipal Government signed a strategic cooperation agreement on vaccine innovation between China and France. Both sides aim to broaden and deepen cooperation improving high-quality vaccine accessibility for Chinese people, building disease prevention capacity, developing and promoting the use of innovative digital health technologies and applications.

| Facts and figures |
| Provide preventative immunization to more than 11 million Chinese people in 2019 |

| | Explore new models for expedited introduction of the most premium vaccines in the world |
| | Empower Shenzhen as a pilot Integrated Digital Health City |
| | Plans to establish China’s first world class vaccine innovation center in Shenzhen |

| As of the end of 2019 |
| 120 maternity hospitals have offered offline vaccination courses or videos |
| organizing a total of 800 training sessions |

| Building Strategic Partnership with Shenzhen Government on Sino-French Vaccine Innovation |
| In November 2019, Sanofi and the Shenzhen Municipal Government signed a strategic cooperation agreement on vaccine innovation between China and France. Both sides aim to broaden and deepen cooperation improving high-quality vaccine accessibility for Chinese people, building disease prevention capacity, developing and promoting the use of innovative digital health technologies and applications. |
Sanofi has 3 international production bases in China (2 prescription drug manufacturing sites respectively in Beijing and Hangzhou and 1 vaccine manufacturing site in Shenzhen), and 4 research and development bases (focusing on research of unmet medical needs in oncology, immune and metabolic diseases), and a digital innovation center.

**Increasing investment in R&D and production in China**

Sanofi established China’s first global research institute in Suzhou, and plans to recruit 30-50 local Chinese scientific research talents. The annual investment is expected to be 20 million euros annually in the next five years.

Sanofi China will invest RMB 500 million to the global R&D operation center and Sanofi China Midwest Operations and Innovation Center in Chengdu.

Sanofi has increased investment in the Beijing manufacturing site to strengthen the insulin glargine product line.

**Future development plan**

- Sanofi established China’s first global research institute in Suzhou, and plans to recruit 30-50 local Chinese scientific research talents. The annual investment is expected to be 20 million euros annually in the next five years.
- Sanofi China will invest RMB 500 million to the global R&D operation center and Sanofi China Midwest Operations and Innovation Center in Chengdu.
- Sanofi has increased investment in the Beijing manufacturing site to strengthen the insulin glargine product line.

**Facts & Figures**

- **Local R&D Investment (yuan)**
  - 2017: 279+ Million
  - 2018: 350+ Million
  - 2019: 610+ Million

- **Number of R&D Personnel**
  - 2017: 250
  - 2018: 293
  - 2019: 326

**Helping “Made in China” happen in the healthcare sector**

Sanofi has given full play to the strength of China R&D Center and Asia-Pacific R&D Headquarters, while embracing an open and cooperative R&D model to work with Chinese scientists. So far, the company has built strategic collaboration with China’s top scientific research institution on more than 60 projects.

In 2019, the “Shared Sunshine-Clinical Research Cooperation Project on Major Diseases”, initiated by the Bethune Charitable Foundation and supported by Sanofi China, was officially launched. Targeting first-line clinicians, this project will sponsor 15 clinical trials in the fields of oncology, blood diseases, solid organ transplantation, and neurology for a duration of 3 years, backed by a total of 3.7 million yuan. It aims to promote disciplinary innovation and talent training to contribute to the ultimate goals of the Healthy China initiative.
Engage with Communities

Helping employees to actualize their dreams and grow their potential

Sanofi China adheres to the Group’s global talent development concept of “One Sanofi, One HR”, and is committed to providing every employee with good training and development opportunities to help them “showcase every side, and outperform every day”.

**Diversity and equity**

We recognize and respect employee diversity in our teams, and constantly strive to create an encouraging, creative, diverse, non-discriminatory, and respectful work environment for each employee.

![Composition of Sanofi China employees in 2019](image)

In order to fully understand the needs of employees, we have organized various forms of communication between management team and employees, such as regular Townhall and breakfast meetings with company’s president. Employee satisfaction surveys are carried out every year in order to push continuous improvement of enterprise management based on employee feedback.

**Employee Health and Safety**

To ensure that employees have a healthy and comfortable working environment, Sanofi China HSE Department conducts daily safety inspections of the workplace and carries out various safety protection measures to eliminate potential health and safety risks.

**“Bwell!” workplace health project: looking after employees’ physical and mental health**

Since the introduction of this project in China, we have proactively helped employees to prevent safety risks in a reasonable fashion, have established three health pillars of a healthy diet, regular exercise and good working conditions, and have consistently provided personal health management programs for employees.

**Facts & Figures**

<table>
<thead>
<tr>
<th>Number of Employees that have received HSE training (person-time)</th>
<th>Average time of HSE trainings that employees take (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>1,583</td>
</tr>
<tr>
<td>2018</td>
<td>1,637</td>
</tr>
<tr>
<td>2019</td>
<td>3,169</td>
</tr>
<tr>
<td>2017</td>
<td>11</td>
</tr>
<tr>
<td>2018</td>
<td>12.5</td>
</tr>
<tr>
<td>2019</td>
<td>12</td>
</tr>
</tbody>
</table>

**Bwel! workplace health project**

A positive workplace health project: looking after employees’ physical and mental health

Since the introduction of this project in China, we have proactively helped employees to prevent safety risks in a reasonable fashion, have established three health pillars of a healthy diet, regular exercise and good working conditions, and have consistently provided personal health management programs for employees.

**Employee participation time (hours)**

- Number of China Offices covered: 11
- Accumulated number of activities: 7
- Number of employee participants: 25,634
- Employees: 27,969
- Male employees: 54%
- Female employees: 47%

- Age 30 and under: 38%
- Age 31-40: 54%
- Age 41 and above: 8%

- Number of activities: 7
- Participation: 27,969
- Average time of HSE trainings: 11 hours
- Total HSE training time for employees: 3,169 person-time

**Employee Health and Safety**

- Employee participation time (hours)
- Number of China Offices covered: 11
- Accumulated number of activities: 7
- Number of employee participants: 25,634
- Employees: 27,969
- Male employees: 54%
- Female employees: 47%

- Age 30 and under: 38%
- Age 31-40: 54%
- Age 41 and above: 8%

- Number of activities: 7
- Participation: 27,969
- Average time of HSE trainings: 11 hours
- Total HSE training time for employees: 3,169 person-time
Sanofi China takes talent development as a fundamental pillar in its corporate strategy. By driving innovation, and building a Magnet of Talents through a diversified, multi-dimensional approach, we strive to ensure that employees can give full play to their talents and have a rewarding experience at Sanofi.

**Magnet of Talents Project**

- **Strong Culture & EVP to attract talents**: Multiple platforms & paths for internal talent development
- **Creative & comprehensive learning offerings**: through online and offline for capability
- **Empower Development**: Inspire Your Journey
- **Empower Learning**: Empower People
- **Empower Rewards**: Competitive & inclusive compensation and benefits for talent attraction and retention
- **Empower Simplification**: Smart digital platform for empowering a simplified employees’ life cycle
- **Empower Caring**: Diversified & holistic caring programs & employee activities for team engagement

Through Sanofi University, we provide employees with multi-dimensional online (E-learning, webcast classes) and offline (classroom lectures) combined training courses, and work to meet all-round and multi-level employee training needs. At the same time, the company has carried out several other projects, such as establishing an internal job transfer mechanism and the Millennium Club, to help employees diversify their careers.

**Facts & Figures**

- **Training time per person (hours)**
  - 2017: 19.61
  - 2018: 24.13
  - 2019: 32.65

- **In 2019, employee classroom training time totaled** 458,580 hours
- **A total number of courses were offered** 724

<table>
<thead>
<tr>
<th>Year</th>
<th>Staff</th>
<th>Mid-level Management</th>
<th>Senior Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>47.82</td>
<td>63.64</td>
<td>45.68</td>
</tr>
<tr>
<td>2018</td>
<td>57.50</td>
<td>37.75</td>
<td>36.47</td>
</tr>
<tr>
<td>2019</td>
<td>63.64</td>
<td>45.68</td>
<td>36.47</td>
</tr>
</tbody>
</table>

Sanofi China has established a performance management system and career development plans for employees to encourage the continuous improvement of company performance and personal growth.

<table>
<thead>
<tr>
<th>Metric</th>
<th>Percentage of employees covered by the career development plan</th>
<th>Number of Chinese employees promoted</th>
<th>Number of female employees as a percentage of the total number within mid-level management</th>
<th>Number of employees sent to foreign countries for rotation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>45%</td>
<td>338</td>
<td>44%</td>
<td>9</td>
</tr>
<tr>
<td>2018</td>
<td>46%</td>
<td>594</td>
<td>52%</td>
<td>12</td>
</tr>
<tr>
<td>2019</td>
<td>73%</td>
<td>623</td>
<td>54%</td>
<td>8</td>
</tr>
</tbody>
</table>
Serving the community with our knowledge and expertise

Sanofi China actively participates in humanitarian assistance and disaster relief activities, cooperating with governments, public welfare organizations, and other partners to provide funds and pharmaceuticals to people in need, in order to fulfill our long-term commitment to the ideal of "In China, for China".

Aubagio® Patient Assistance Program

In 2018, Together with the China Primary Healthcare Foundation, Sanofi launched Aubagio® Patient Assistance Program. Once enrolled, eligible patients with multiple sclerosis (MS) can reduce their annual drug treatment at a discount of more than 40%, and patients living on a subsistence allowance may have the chance to receive free medication.

In the same year, Sanofi, together with the Neurology Society of the Chinese Medical Association and the China International Association for the Promotion of Health Care, released the Report on the Living Status of Chinese Patients with Multiple Sclerosis, with the goal of increasing overall social attention to MS, promoting its standardized diagnosis and treatment, and providing a basis for improving the social security system.

Devotion to community for a better future

Sanofi is convinced that as corporate citizens, pharmaceutical companies should give full play to their advantages and expertise, in order to give back to society. They should also contribute to the healthy and sustainable development of society as a whole. As such, we encourage employees to actively participate in social welfare undertakings, and to help more people lead fulfilling and successful lives.

Support scientific research personnel training

Sanofi China launched the Sanofi-SIBS Outstanding Young Talent Fellowship, which aims to provide financial support for new talents in the Shanghai Institute for Biological Science (SIBS), and to encourage more talents with scientific research and innovation capabilities to actively participate in China’s frontier life sciences research and make active contributions to the research of cancers, diabetes, and hepatitis, as well as other diseases of high prevalence in China.

By the end of 2019 a total of 230 researchers have received the fellowship

Engage with Communities | P 17
We should be able to love ourselves, and if we have any power left over, we should also help others. We can feel the true meaning of life in the process of helping others to help themselves. This allows us to grow.

— Li Yina, Sanofi Guangzhou Volunteer Group

With the continuous growth of the Sanofi Volunteers Group, we continue to promote the standardized management of employee volunteer services. By innovating in volunteer service methods, and engaging professional CSR firms, we provide Sanofi Volunteer Stars professional volunteer activity training; at the same time, we provide every employee with a day of “paid volunteer leave” to encourage them to contribute their skills and expertise to promote sustainable social development outside of the workplace.

Facts & Figures

From 2011, Sanofi China has supported the Croisements festival for 9 consecutive years. By inviting French artists to engage in creative activities with sick children, we aim to ignite their imagination and creative inspiration, in order to provide them and their families with much-needed laughter and support.

Since 2010, Sanofi China and Liangshan Yi Nationality Women and Children Development Center have launched the “Sanofi Love Class” to provide basic living materials, boarding education, and health care education for children who have lost their caregivers in Liangshan Prefecture. Sanofi also supports the inheritance of Liangshan Yi culture to promote unity between the Yi and Han nationalities. In 2018, the first group of children who had received Sanofi’s assistance successfully completed nine years of compulsory education and commenced vocational or higher education.

In 2017, Li Yina received the Sanofi Charity Star Award
In 2018, she was awarded Guangzhou Golden Ribbon Excellent Volunteer

“...We should be able to love ourselves, and if we have any power left over, we should also help others. We can feel the true meaning of life in the process of helping others to help themselves. This allows us to grow”.

— Li Yina, Sanofi Guangzhou Volunteer Group

As of the end of 2019, nearly 2.59 million yuan was invested to help 291 children who have lost their caregivers

Support the Croisements festival to deepen the dialogue between art and health

Empowering homeless children in Liangshan

Voice from Sanofi Volunteers
The outbreak of COVID-19 in early 2020 deeply moved the hearts of people across the country, and the people of Sanofi China are no exception: the company has taken immediate actions and actively donated protective suppliers to assist health workers in their fight against the epidemic.

Sanofi announced a donation of 1 million yuan to the China Red Cross Foundation for the purchase of personal protective equipment.

Sanofi Pasteur donated 500 thousand yuan worth of medical supplies (i.e., throat swabs) to Hubei CDC.

Work together with all fields to develop vaccines and therapies to build health fortress
- Announced that Sanofi will respectively collaborate with the Biomedical Advanced Research and Development Authority (BARDA), Translate Bio, GlaxoSmithKline (GSK) to develop COVID-19 vaccine
- Collaborate with Luminostics to develop smartphone-based COVID-19 monitoring tools

Resume production in time to ensure continuous supply of medicines and vaccines
Our 3 manufacturing sites worked closely in line with the epidemic prevention guidance of governments, ensuring all key business continuity to fulfill our commitment.

Unite all social resources in the race against time
During the critical period of combatting the epidemic, Sanofi China established a dedicated working group to engage stakeholders from all sectors to quickly distribute medicines to epileptic children in Hubei who lacked medication, due to the epidemic.

Expand diversified channels to benefit chronically ill patients
During the epidemic, Sanofi actively built a mobile platform for patients and launched the Convenient Pharmacy Mapping, covering more than 70,000 retail pharmacies across the country, to help chronically ill patients to easily locate pharmacies and their drug reimbursement information. Sanofi also collaborated with Nepstar and Laobaixing pharmacy chains in the introduction of "mobile pharmacies", to have medications delivered to people’s homes in an effort to eliminate cross-infection. In addition, using its strengths and expertise in the treatment of chronic diseases such as cardiovascular disease and diabetes, Sanofi joined hands with many Internet hospitals, including JD.com, Ali Health, and Yiyaowang.com, to provide patients with online consultation, follow-up consultation, and drug delivery services, and to organize virtual meetings with physicians through live broadcasts.
Sanofi China has always been committed to protecting natural resources in all industrial affairs, R&D, and business activities. By continuously improving its environmental management system, carrying out energy-saving management, and promoting the rational use of resources, the company aims to minimize the ecological footprint caused by various activities it has conducted for its operation.

**Five core commitments of Planet Mobilization**

- **Carbon footprint**: Reduce carbon emissions by 50% between 2015 and 2025.
- **Water resources**: Reduce water consumption by 10% between 2015 and 2025.
- **Waste**: By 2025 recycling rate will reach 90%.
- **Drugs entering the natural environment**: By 2025, all manufacturing sites will implement product life cycle management plans.
- **Biodiversity**: By 2025, Biodiversity Awareness Program will be implemented in 100% of Sanofi’s operational locations.

Sanofi China’s three manufacturing sites have all obtained environmental management system certification, strictly control waste disposal and water resources management, and hand over hazardous waste to professional parties for harmless treatment. The waste water generated in the production process will be pretreated by the sewage cooling tank and then discharged into the regulating tank. After professional treatment such as impurity removal, degradation and precipitation, it will enter the municipal pipe network.

### Measures taken by Sanofi China’s manufacturing sites to reduce energy use (2017-2019)

- **Reducing the use of water resources**
  - Continuously optimize effluent segregation to further reduce waste water discharge
  - Optimize the recovery of steam condensate as well as the cleaning process
  - Reduce the use of purified water, thereby reducing the overall discharge of wastewater

- **Reduce the use of packaging**
  - Use cold chain trucks to transport medicines to save the use of cold boxes

- **Optimizing energy use**
  - Optimize the operation of air conditioning systems by means of intermittent operation, improving equipment cleaning effects, etc., to reduce energy consumption
  - Reduce power consumption by reducing the operation frequency of the chilled water pump, which circulates the chilled water back to the aseptic area, optimize the operation mode of the air conditioning unit to reduce the consumption of electricity and steam
  - Refrigerator waste heat recovery and utilization
Sanoﬁ China has always been committed to protecting natural resources in all industrial affairs, R&D, and business activities. By continuously improving its environmental management system, carrying out energy-saving management, and promoting the rational use of resources, the company aims to minimize the ecological footprint caused by various activities it has conducted for its operation.

### Five core commitments of Planet Mobilization

- **Carbon footprint**
  - Reduce carbon emissions by 50% between 2015 and 2025 of Sanoﬁ’s operational locations.

- **Drugs entering the natural environment**
  - Reduce water consumption by 10%

- **Waste**
  - By 2025 recycling rate will reach 90%
  - By 2025, all manufacturing sites will implement product life cycle management plans.

- **Biodiversity**
  - By 2025, Biodiversity Awareness Program will be implemented in 100%

Sanoﬁ China’s three manufacturing sites have all obtained environmental management system certification, strictly control waste disposal and water resources management, and hand over hazardous waste to professional parties for harmless treatment. The waste water generated in the production process will be pretreated by the sewage cooling tank and then discharged into the regulating tank. After professional treatment such as impurity removal, degradation and precipitation, it will enter the municipal pipe network.

### Facts & Figures

<table>
<thead>
<tr>
<th>Beijing site</th>
<th>Hangzhou site</th>
<th>Shenzhen site</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Carbon emission</strong> (ton/ RMB 10,000 production value)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.0091</td>
<td>0.0055</td>
<td>0.0476</td>
</tr>
<tr>
<td>0.0086</td>
<td>0.0052</td>
<td>0.0409</td>
</tr>
<tr>
<td>0.0092</td>
<td>0.0045</td>
<td>0.0425</td>
</tr>
</tbody>
</table>

| **Water consumption** (ton/ RMB 10,000 production value) |
| 0.0632 | 0.0334 | 0.1766 |
| 0.0657 | 0.0253 | 0.1100 |
| 0.0601 | 0.0224 | 0.1402 |

| **Wastewater discharge** (ton/ RMB 10,000 production value) |
| 0.0302 | 0.0301 | 0.1263 |
| 0.0271 | 0.0228 | 0.0829 |
| 0.0296 | 0.0203 | 0.0779 |

| **Electricity consumption** (mWh/ RMB 10,000 production value) |
| 0.0011 | 0.0006 | 0.0059 |
| 0.0010 | 0.0006 | 0.0050 |
| 0.0010 | 0.0005 | 0.0051 |

| **Non-hazardous waste discharge** (g/ RMB 10,000 production value) |
| 272.99 | 140.50 | 895.45 |
| 216.06 | 119.97 | 408.82 |
| 245.68 | 127.32 | 940.43 |

| **Hazardous waste discharge** (g/ RMB 10,000 production value) |
| 10.05 | 26.24 | 56.60 |
| 5.69 | 59.43 | 22.30 |
| 59.99 | 20.31 | 49.67 |

To enhance employees’ environmental awareness, Sanofi China has initiated annual Sanofi World Environment Day activities at its manufacturing sites. It also conducts environmental protection experience activities, and regularly promotes the theme of carbon emission reduction.
<table>
<thead>
<tr>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>GRI 101 Foundation</td>
<td></td>
</tr>
<tr>
<td>GRI 102 General Disclosures</td>
<td></td>
</tr>
</tbody>
</table>

### Organizational Profile

- 102-1 Name of the organization: P1
- 102-2 Activities, brands, products, and services: P1
- 102-3 Location of headquarters: P1.4
- 102-4 Location of operations: P1.4
- 102-5 Ownership and legal form: P1
- 102-6 Markets served: P1/P7
- 102-7 Scale of the organization: P1
- 102-8 Information on employees and other workers: P1, P15

### Strategy

- 102-9 Supply chain: P5
- 102-10 Significant changes to the organization and its supply chain: /
- 102-11 Precautionary Principle or approach: P6
- 102-12 External initiatives: /

### Ethics and Integrity

- 102-13 Values, principles, standards, and norms of behavior: P4
- 102-14 Statement from senior decision-maker: P2
- 102-15 Key impacts, risks, and opportunities: P2-P5

### Stakeholder Engagement

- 102-16 List of stakeholder groups: P3
- 102-17 Identifying and selecting stakeholders: P3
- 102-18 Approach to stakeholder engagement: P3
- 102-19 Key topics and concerns raised: P5

### Reporting Practice

- 102-20 Defining report content and topic boundaries: P3
- 102-21 List of material topics: P3
- 102-22 Restatements of information: /
- 102-23 Changes in reporting: P23
- 102-24 Reporting period: P23
- 102-25 Date of most recent report: P23
- 102-26 Reporting cycle: P23
- 102-27 Contact point for questions regarding the report: P23

### GRI Content Index

<table>
<thead>
<tr>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>GRI 200 Economic</td>
<td></td>
</tr>
<tr>
<td>GRI 201 Management approach</td>
<td></td>
</tr>
<tr>
<td>GRI 202 Market Presence</td>
<td></td>
</tr>
<tr>
<td>GRI 203 Indirect Economic Impacts</td>
<td></td>
</tr>
<tr>
<td>GRI 204 Procurement Practices</td>
<td></td>
</tr>
<tr>
<td>GRI 205 Anti-corruption</td>
<td></td>
</tr>
<tr>
<td>GRI 206 Anti-competitive Behavior</td>
<td></td>
</tr>
<tr>
<td>GRI 207 Water</td>
<td></td>
</tr>
<tr>
<td>GRI 208 Emissions</td>
<td></td>
</tr>
<tr>
<td>GRI 209 Environmental Compliance</td>
<td></td>
</tr>
<tr>
<td>GRI 210 Environmental Assessment</td>
<td></td>
</tr>
</tbody>
</table>

### GRI 400 Social

<table>
<thead>
<tr>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>GRI 401 Employment</td>
<td></td>
</tr>
<tr>
<td>GRI 403 Health and Safety</td>
<td></td>
</tr>
<tr>
<td>GRI 404 Training and Education</td>
<td></td>
</tr>
<tr>
<td>GRI 405 Diversity and Equal Opportunity</td>
<td></td>
</tr>
<tr>
<td>GRI 406 Non-discrimination</td>
<td></td>
</tr>
<tr>
<td>GRI 408 Child Labor</td>
<td></td>
</tr>
<tr>
<td>GRI 409 Forced or Compulsory Labor</td>
<td></td>
</tr>
<tr>
<td>GRI 411 Rights of Indigenous Peoples</td>
<td></td>
</tr>
<tr>
<td>GRI 413 Local Communities</td>
<td></td>
</tr>
<tr>
<td>GRI 414 Consumer Health and Safety</td>
<td></td>
</tr>
<tr>
<td>GRI 417 Marketing and Labeling</td>
<td></td>
</tr>
<tr>
<td>GRI 418 Customer Privacy</td>
<td></td>
</tr>
<tr>
<td>GRI 419 Socioeconomic Compliance</td>
<td></td>
</tr>
</tbody>
</table>

This report has been prepared in accordance with the GRI Standards: Core option.
Awards & Recognition

- In 2018
  China’s Top 300 CSR (Corporate Social Responsibilities) Enterprises
  ranking the first among multinational pharmaceutical companies

- 2015 - 2019
  China CSR Outstanding Enterprise Award

- 2016 - 2018
  China’s Best Corporate Citizen Annual Award

- 2017-2019
  Top Employer in China awarded by the Top Employers Institute

- 2018 - 2019
  Top Employer in Asia Pacific awarded by the Top Employers Institute

- In 2019
  "The Most Attractive Employers Top20" by health/medical students in the Universum
  2019 China’s Most Attractive Employers Rankings

- In 2019
  Driving Innovation Award and Outstanding Contribution to Innovation Award on
  China CSR 2019 List

Additional Information about Sanofi CSR Report

- **Time Range**
  The information contained in this report is mainly from January 2017 to December 2019, and some information is extended to 2020 or traces back to previous years.

- **Release Frequency**
  Sanofi China releases its social responsibility report biannually. This report is Sanofi China’s fourth corporate social responsibility report.

- **Business Units Contributing to this Report**
  The contents contained in this CSR report is contributed by Sanofi’s all businesses units in China, including pharmaceutical business and vaccine business (Sanofi Pasteur), 12 regional offices, 3 production sites, and 4 R&D bases.

- **Source of Information**
  The information and data disclosed in this report are derived from the company’s public information, internal documents, and related statistical data.

- **Basis of Preparation**
  This report was prepared with reference to the unified standards of the GRI Sustainability Report 2016 and Sanofi Group’s social responsibility information disclosure requirements.

- **Referral Instructions**
  For ease of presentation, this report uses "we" in reference to “Sanofi China” and "Sanofi* Group" to mean "Sanofi Group".

- **Report Access**
  This report is available in both print and electronic versions. You can log in to www.sanofi.cn to obtain the electronic version; if you would like to obtain the printed version, or have questions or suggestions about this report, you can send an email to CSR.China@sanofi.com.